Literature DB >> 24196615

[Chronic liver diseases--new therapy. Are biopsies necessary?].

A Tannapfel1.   

Abstract

Chronic liver disease can often reliably be assessed only by examination of biopsy material. In this article the possible indications for liver biopsy in viral hepatitis B and C, autoimmune liver disease, steatohepatitis and hereditary metabolic diseases are described. A biopsy may be useful in cases with unclear clinical or serological situations or with questionable chronicity and comorbidities. The assessment of biopsy material should be based on guideline-based classification systems. The value of biopsy diagnosis benefits from a close interdisciplinary clinical pathological cooperation.

Entities:  

Mesh:

Year:  2013        PMID: 24196615     DOI: 10.1007/s00292-013-1808-8

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  9 in total

Review 1.  [Bioptic diagnosis of chronic hepatitis. Results of an evidence-based consensus conference of the German Society of Pathology, of the German Society for Digestive and Metabolic Diseases and of Compensated Hepatitis (HepNet)].

Authors:  P Schirmacher; W E Fleig; A Tannapfel; C Langner; V Dries; L Terracciano; H Denk; H P Dienes
Journal:  Pathologe       Date:  2004-09       Impact factor: 1.011

2.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Gastroenterology       Date:  2012-05-15       Impact factor: 22.682

3.  The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury.

Authors:  Ayako Suzuki; Elizabeth M Brunt; David E Kleiner; Rosa Miquel; Thomas C Smyrk; Raul J Andrade; M Isabel Lucena; Agustin Castiella; Keith Lindor; Einar Björnsson
Journal:  Hepatology       Date:  2011-08-08       Impact factor: 17.425

4.  [Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline].

Authors:  M Cornberg; U Protzer; J Petersen; H Wedemeyer; T Berg; W Jilg; A Erhardt; S Wirth; C Sarrazin; M M Dollinger; P Schirmacher; K Dathe; I B Kopp; S Zeuzem; W H Gerlich; M P Manns
Journal:  Z Gastroenterol       Date:  2011-07-11       Impact factor: 2.000

5.  [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection].

Authors:  C Sarrazin; T Berg; R S Ross; P Schirmacher; H Wedemeyer; U Neumann; H H Schmidt; U Spengler; S Wirth; H H Kessler; M Peck-Radosavljevic; P Ferenci; W Vogel; D Moradpour; M Heim; M Cornberg; U Protzer; M P Manns; W E Fleig; M M Dollinger; S Zeuzem
Journal:  Z Gastroenterol       Date:  2010-01-29       Impact factor: 2.000

Review 6.  Liver biopsies in chronic viral hepatitis: beyond grading and staging.

Authors:  Rachel Hudacko; Neil Theise
Journal:  Arch Pathol Lab Med       Date:  2011-10       Impact factor: 5.534

Review 7.  Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue.

Authors:  Kirsten Muri Boberg; Roger W Chapman; Gideon M Hirschfield; Ansgar W Lohse; Michael P Manns; Erik Schrumpf
Journal:  J Hepatol       Date:  2010-09-18       Impact factor: 25.083

Review 8.  The indications for liver biopsy.

Authors:  Andrea Tannapfel; Hans-Peter Dienes; Ansgar W Lohse
Journal:  Dtsch Arztebl Int       Date:  2012-07-09       Impact factor: 5.594

Review 9.  [Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines].

Authors:  A Tannapfel; H Denk; H P Dienes; C Langner; P Schirmacher; M Trauner; B Flott-Rahmel
Journal:  Pathologe       Date:  2010-05       Impact factor: 1.011

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.